YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
NeurAxis, Inc. Total national coverage footprint for PENFS increases to over 120 million covered lives CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical technolog…
Neuraxis, Inc.'s NRXS investors have been gaining from the stock over the past year. Shares of the Carmel, IN-based medical technology company gained 136.6% in the past year against the industry's 12.2% decline. It has also outperformed th…
Is Eastman Kodak Company (KODK) now at an operational inflection point? It has been a long road back from digital photography disintermediation, but Eastman Kodak Company (KODK) is showing green shoots.Zacks Investment Research Image Sourc…
NeurAxis, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Reve…
CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children…
Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund" Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% in the first quarter of 2026 due to a…
Shares of NeurAxis, Inc. NRXS have gained 2.5% since the company reported earnings for the quarter ended March 31, 2026, outperforming the S&P 500 Index’s 1.3% increase over the same period. Over the past month, the stock advanced 13.5%, a…
NeurAxis (NRXS) specializes in neuromodulation therapies, targeting chronic abdominal pain in pediatric and adult patients. NRXS exhibits exceptional technical momentum with shares trading at new all-time highs. The stock is up more than 3…
CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in ch…
For Immediate Release Chicago, IL – May 5, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial marke…
Monday, May 4, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Walmart Inc. (WMT) and Micron Tec…
CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in childre…
Shares of NeurAxis, Inc. NRXS have gained 4.6% since the company reported results for the quarter ended Dec. 31, 2025, against a 0.8% decline in the S&P 500 over the same period. Over the past month, the stock has rallied sharply, gaining…
NeurAxis, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Operational Context Performance attribution shifted in Q1 2026 from securing regulatory milestones to active commercial execution following the January 1 effective…
Monday, January 5, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Bank of America Corp. (…
Achieves significant expansion of NeurAxis’ total addressable marketClearance now includes patients aged “8 years and older”Expanded age indication will utilize the upcoming January 1st, 2026, Category I CPT code to report PENFS procedures…
For Immediate Release Chicago, IL – September 17, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financia…
Tuesday, September 16, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), IBM Corp. (IBM) and Merck…
* NeurAxis press release [https://seekingalpha.com/pr/20197157-neuraxis-reports-strong-second-quarter-2025-financial-results-driven-by-a-46-percent-growth] (NYSE:NRXS [https://seekingalpha.com/symbol/NRXS]): Q2 Net loss in the second quart…
Neuraxis, Inc. (NYSE American:NRXS), a $23 million market cap healthcare company with annual revenue of $2.93 million and impressive year-over-year growth of 27.5%, disclosed on Thursday that it has terminated its license and collaboration…
For Immediate Release Chicago, IL – June 27, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial mar…
Shares of NeurAxis, Inc. NRXS have gained 13.3% since the company reported its earnings for the quarter ended March 31, 2025. This compares to the S&P 500 Index’s 4.3% growth over the same time frame. Over the past month, the stock gained…
For Immediate Release Chicago, IL – May 1, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial marke…
Wednesday, April 30, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson (JNJ) a…
CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in…
CARMEL, Ind., Nov. 15, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in c…
CARMEL, Ind., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in c…
CARMEL, Ind., Nov. 08, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in c…
CARMEL, Ind., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions i…
CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in…
CARMEL, Ind., Sept. 13, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions…
CARMEL, Ind., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions i…
CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in…
CARMEL, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions i…
CARMEL, Ind., Aug. 22, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions i…
CARMEL, Ind., Aug. 17, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in…